

# Bruce A C Cree,, Mas

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1287737/bruce-a-c-cree-mas-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188 papers	15,627 citations	58 h-index	123 g-index
210 ext. papers	19,094 ext. citations	9 avg, IF	6.37 L-index

#	Paper	IF	Citations
188	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , <b>2011</b> , 476, 214-9	50.4	1948
187	Risk alleles for multiple sclerosis identified by a genomewide study. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 851-62	59.2	1327
186	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , <b>2013</b> , 45, 1353-60	36.3	934
185	An open label study of the effects of rituximab in neuromyelitis optica. <i>Neurology</i> , <b>2005</b> , 64, 1270-2	6.5	516
184	Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 10713-10718	11.5	453
183	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , <b>2018</b> , 391, 1263-1273	40	422
182	Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1443-8		376
181	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 767-78	5.6	357
180	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , <b>2019</b> , 365,	33.3	309
179	Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. <i>American Journal of Human Genetics</i> , <b>2004</b> , 74, 160-7	11	274
178	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1075-1084	40	271
177	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i> , <b>2018</b> , 90, 777-788	6.5	261
176	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1352-1363	40	247
175	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 2813-24	5.6	246
174	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , <b>2016</b> , 80, 499-510	9.4	229
173	Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. <i>Annals of Neurology</i> , <b>2012</b> , 72, 53-64	9.4	224
172	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2481-2489	40	221

171	A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. <i>Nature Genetics</i> , <b>2005</b> , 37, 1113-8	36.3	220
170	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , <b>2004</b> , 63, 2039-45	6.5	214
169	Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 18680-5	11.5	204
168	Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 4777-82	11.5	182
167	Inclusion of brain volume loss in a revised measure of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1297-305	5	169
166	Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. <i>Neurology</i> , <b>2011</b> , 76, 686-92	6.5	167
165	B cell exchange across the blood-brain barrier in multiple sclerosis. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 4533-43	15.9	163
164	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 257-67	24.1	156
163	Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e76	9.1	141
162	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , <b>2014</b> , 82, 1491-8	6.5	141
161	Silent progression in disease activity-free relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2019</b> , 85, 653-666	9.4	135
160	Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. <i>Brain</i> , <b>2009</b> , 132, 250-9	11.2	132
159	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. <i>Annals of Neurology</i> , <b>2014</b> , 76, 568-80	9.4	131
158	Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e453	9.1	114
157	Neuromyelitis optica. <i>Seminars in Neurology</i> , <b>2002</b> , 22, 105-22	3.2	112
156	Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?. <i>JAMA Neurology</i> , <b>2014</b> , 71, 269-70	17.2	111
155	Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. <i>Neurology</i> , <b>2008</b> , 71, 1390-5	6.5	108
154	Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154335	3.7	105

153	Treatment of Multiple Sclerosis: A Review. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 1380-1390.e2	2.4	99
152	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1021-1033	24.1	98
151	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1009-1020	24.1	96
150	Gut microbiome analysis in neuromyelitis optica reveals overabundance of <i>Clostridium perfringens</i> . <i>Annals of Neurology</i> , <b>2016</b> , 80, 443-7	9.4	95
149	Natalizumab dosage suspension: are we helping or hurting?. <i>Annals of Neurology</i> , <b>2010</b> , 68, 395-9	9.4	92
148	Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , <b>2018</b> , 90, e1815-e1821	18.1	91
147	Microcystic inner nuclear layer abnormalities and neuromyelitis optica. <i>JAMA Neurology</i> , <b>2013</b> , 70, 629-33	17.2	91
146	Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. <i>Human Molecular Genetics</i> , <b>2010</b> , 19, 953-62	5.6	91
145	Ocrelizumab and Other CD20 B-Cell-Depleting Therapies in Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2017</b> , 14, 835-841	6.4	87
144	Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1345-56		86
143	Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. <i>Journal of Immunology</i> , <b>2008</b> , 181, 5473-80	5.3	83
142	Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2009</b> , 80, 1002-5	5.5	78
141	Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. <i>Archives of Neurology</i> , <b>2009</b> , 66, 226-33		71
140	Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. <i>Journal of Neurology</i> , <b>2017</b> , 264, 316-326	5.5	70
139	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i> , <b>2018</b> , 90, 789-800	6.5	67
138	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1359-1366	17.2	67
137	In vivo evidence of glutamate toxicity in multiple sclerosis. <i>Annals of Neurology</i> , <b>2014</b> , 76, 269-78	9.4	67
136	Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. <i>Archives of Neurology</i> , <b>2010</b> , 67, 1201-8		66

135	Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 68, 145-50	9.4	66
134	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2015</b> , 72, 897-904	17.2	63
133	Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2005</b> , 116, 453-9	11.5	63
132	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. <i>Genes and Immunity</i> , <b>2010</b> , 11, 397-405	4.4	62
131	Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. <i>Seminars in Neurology</i> , <b>2012</b> , 32, 97-113	3.2	61
130	Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 4194-205	5.6	58
129	Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. <i>Journal of Clinical Neuroscience</i> , <b>2011</b> , 18, 997-8	2.2	58
128	Response to interferon beta-1a treatment in African American multiple sclerosis patients. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1681-3		58
127	Vitamin D in African Americans with multiple sclerosis. <i>Neurology</i> , <b>2011</b> , 76, 1824-30	6.5	56
126	Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. <i>Neurology</i> , <b>2009</b> , 72, 1760-5	6.5	55
125	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. <i>Neurology: Genetics</i> , <b>2016</b> , 2, e87	3.8	52
124	Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. <i>Annals of Neurology</i> , <b>2004</b> , 55, 793-800	9.4	52
123	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 862-72	5	51
122	Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 835-43	5	51
121	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2010</b> , 292, 28-35	3.2	50
120	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , <b>2019</b> , 32, 365-377	7.1	50
119	Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. <i>JAMA Neurology</i> , <b>2014</b> , 71, 840-7	17.2	48
118	Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	48

117	Gut microbiota-specific IgA B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , <b>2020</b> , 5,	28	48
116	A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. <i>PLoS ONE</i> , <b>2010</b> , 5, e11296	3.7	46
115	Neuromyelitis optica: diagnosis, pathogenesis, and treatment. <i>Current Neurology and Neuroscience Reports</i> , <b>2008</b> , 8, 427-33	6.6	46
114	Genetic risk variants in African Americans with multiple sclerosis. <i>Neurology</i> , <b>2013</b> , 81, 219-27	6.5	45
113	An ImmunoChip study of multiple sclerosis risk in African Americans. <i>Brain</i> , <b>2015</b> , 138, 1518-30	11.2	44
112	Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. <i>Genes and Immunity</i> , <b>2006</b> , 7, 310-5	4.4	44
111	Switching multiple sclerosis patients with breakthrough disease to second-line therapy. <i>PLoS ONE</i> , <b>2011</b> , 6, e16664	3.7	44
110	Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2016</b> , 73, 795-802	17.2	43
109	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 22932-22943	11.5	43
108	Disease-modifying therapies alter gut microbial composition in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e517	9.1	43
107	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , <b>2017</b> , 89, 1584-1593	6.5	42
106	Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2014</b> , 1, e34	9.1	42
105	Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. <i>Brain</i> , <b>2018</b> , 141, 85-98	11.2	41
104	Rituximab in neurological disease: principles, evidence and practice. <i>Practical Neurology</i> , <b>2019</b> , 19, 5-20	2.4	38
103	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. <i>JAMA Network Open</i> , <b>2019</b> , 2, e190570	10.4	37
102	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. <i>Nature Communications</i> , <b>2019</b> , 10, 2236	17.4	36
101	Multiple sclerosis genetics. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2014</b> , 122, 193-209	3	36
100	Precision medicine in chronic disease management: The multiple sclerosis BioScreen. <i>Annals of Neurology</i> , <b>2014</b> , 76, 633-42	9.4	36

99	Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. <i>Neurology</i> , <b>2006</b> , 67, 176-7	6.5	36
98	Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. <i>MSystems</i> , <b>2018</b> , 3,	7.6	36
97	Emerging monoclonal antibody therapies for multiple sclerosis. <i>Neurologist</i> , <b>2006</b> , 12, 171-8	1.6	35
96	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , <b>2012</b> , 79, 285-7	6.5	34
95	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1526-1534	5	32
94	The Gut Microbiome in Neuromyelitis Optica. <i>Neurotherapeutics</i> , <b>2018</b> , 15, 92-101	6.4	31
93	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , <b>2015</b> , 84, 1805-15	6.5	30
92	Refining the association of MHC with multiple sclerosis in African Americans. <i>Human Molecular Genetics</i> , <b>2010</b> , 19, 3080-8	5.6	29
91	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2020</b> , 19, 988-997	24.1	28
90	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , <b>2019</b> , 266, 1182-1193	5.5	28
89	Transient hyperckemia in the setting of neuromyelitis optica (NMO). <i>Muscle and Nerve</i> , <b>2014</b> , 50, 859-62	3.4	26
88	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. <i>Neurology</i> , <b>2021</b> , 96, e376-e386	6.5	26
87	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1255-1262	5	24
86	Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. <i>BMC Neurology</i> , <b>2014</b> , 14, 220	3.1	24
85	Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. <i>Archives of Neurology</i> , <b>2011</b> , 68, 464-8		24
84	Acute inflammatory myelopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2014</b> , 122, 613-67	3	23
83	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , <b>2021</b> , 89, 895-910	9.4	23
82	Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1519-30		22



81	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , <b>2018</b> , 84, 51-63	9.4	21
80	MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2014</b> , 1, e20	9.1	21
79	Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2016</b> , 3, e272	9.1	20
78	Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2019</b> , 86, 671-682	9.4	19
77	Encephalitis of unclear origin diagnosed by brain biopsy: a diagnostic challenge. <i>JAMA Neurology</i> , <b>2015</b> , 72, 66-72	17.2	17
76	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , <b>2015</b> , 262, 326-36	5.5	16
75	Fulminant Demyelinating Diseases of the Central Nervous System. <i>Seminars in Neurology</i> , <b>2015</b> , 35, 656-662	9.6	16
74	Phase IV study of retention on fingolimod injectable multiple sclerosis therapies: a randomized clinical trial. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418774338	6.6	16
73	Onset of secondary progressive MS after long-term rituximab therapy - a case report. <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 46-52	5.3	15
72	Harnessing electronic medical records to advance research on multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 408-418	5	15
71	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1485-1498	15.98	14
70	Secondary Progressive Multiple Sclerosis: New Insights. <i>Neurology</i> , <b>2021</b> , 97, 378-388	6.5	14
69	Prognostic biomarkers of IFN $\beta$ therapy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 894-904	5	13
68	Ovarian aging is associated with gray matter volume and disability in women with MS. <i>Neurology</i> , <b>2018</b> , 90, e254-e260	6.5	13
67	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 346-356	5.3	13
66	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211024997	5	13
65	Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	12
64	Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	12



63	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e533	9.1	11
62	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , <b>2020</b> , 95, e1027-e1040	6.5	11
61	Genetics of primary progressive multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2014</b> , 122, 211-30	3	11
60	Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. <i>JAMA Neurology</i> , <b>2013</b> , 70, 248-51	17.2	11
59	Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2017</b> , 27, 476-480	2.8	10
58	Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 752	4	10
57	Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. <i>General Hospital Psychiatry</i> , <b>2010</b> , 32, 648.e5-8	5.6	10
56	Steering through complexity: management approaches in multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2016</b> , 29, 263-71	7.1	10
55	Characterizing retinal structure injury in African-Americans with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 16-20	4	9
54	Placebo controlled trials in neuromyelitis optica are needed and ethical. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 536-45	4	8
53	Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. <i>Annals of Neurology</i> , <b>2021</b> , 89, 192-193	9.4	8
52	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2020</b> ,	17.2	7
51	Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2021</b> ,	9.4	6
50	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	6
49	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 2219-2226	4.4	5
48	Diagnosis and differential diagnosis of multiple sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , <b>2010</b> , 16, 19-36	3	5
47	Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. <i>Brain</i> , <b>2021</b> , 144, 450-461	11.2	5
46	Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520924594	5	5

45	Effects of COVID-19 "Sheltering in Place" on Activity in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , <b>2021</b> , 11, e216-e218	1.7	5
44	Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6,	9.1	4
43	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOMentum Study.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103352	4	4
42	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 49, 102695	4	4
41	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2052-2061	5	4
40	Acute liver injury in a Glatopa-treated patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e368	9.1	3
39	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1161-1162	5	3
38	Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 50-56	4	3
37	Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e101	9.1	3
36	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1432-1441	5	3
35	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 51, 102844	4	3
34	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 48, 102673	4	3
33	Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	3
32	Statistical Considerations for an Adaptive Design for a Serious Rare Disease. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2016</b> , 50, 375-384	1.2	2
31	2014 multiple sclerosis therapeutic update. <i>Neurohospitalist, The</i> , <b>2014</b> , 4, 63-5	1.1	2
30	Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis. <i>Value in Health</i> , <b>2013</b> , 16, A107	3.3	2
29	Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies		2
28	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103356	4	2

27	Imaging correlates of visual function in multiple sclerosis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235615	3.7	2
26	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2219-2231	5	2
25	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217318819245	2	2
24	Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 103010	4	2
23	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 3722-3730	6	2
22	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.. <i>Neurology and Therapy</i> , <b>2022</b> , 1	4.6	2
21	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221076717	5	2
20	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221083194	5	2
19	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	2
18	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. <i>Journal of Neurology</i> ,	5.5	2
17	Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?". <i>Annals of Neurology</i> , <b>2019</b> , 86, 472-473	9.4	1
16	Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1355-1366	17.2	0
15	Multiple sclerosis: two decades of progress.. <i>Lancet Neurology, The</i> , <b>2022</b> , 21, 211-214	24.1	0
14	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 61, 103747	4	0
13	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 62, 103793	4	0
12	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , <b>2019</b> , 92, 151	6.5	
11	Diagnosing Encephalitis, Not Otherwise Specified-Reply. <i>JAMA Neurology</i> , <b>2015</b> , 72, 726-7	17.2	
10	Switching to fingolimod in PREFERMS: Effect of treatment history and naivety on clinical, MRI and treatment satisfaction outcomes. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 45, 102346	4	

- 9 Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?. *Journal of Neuro-Ophthalmology*, **2018**, 38, 258-262 2.6
- 8 Is there a role for planned natalizumab dosage suspension in mitigating progressive multifocal leukoencephalopathy risk?. *Neurodegenerative Disease Management*, **2011**, 1, 11-14 2.8
- 7 Interferon Beta-1a Treatment and African AmericansReply. *Archives of Neurology*, **2006**, 63, 628
- 6 Identifying falls remotely in people with multiple sclerosis. *Journal of Neurology*, **2021**, 1 5.5
- 5 Reply to "Spinal cord atrophy is a preclinical marker of progressive MS".. *Annals of Neurology*, **2022**, 9.4
- 4 Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615
- 3 Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615
- 2 Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615
- 1 Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615